Deven Choksey recommended Accumulate rating on Divis Laboratories with a target price of Rs 6795 in its research report dated ...

Join us on the Divis Labs Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock.

Stay updated with the Divis Labs Stock Liveblog, your one-stop destination for real-time information and analysis of a ...

The Hyderabad-based pharma company is set to stage a strong financial performance for the July-September period. Here's what analysts expect to see in the drug maker's upcoming earnings report.

ICICI Securities is bearish on Divis Laboratories has recommended sell rating on the stock with a target price of Rs 5400 in its research report dated 09, 2025.

The Hyderabad-based pharmaceutical company's consolidated revenue from operations grew 16 per cent YoY to Rs 2,715 crore in Q2 FY26, against Rs 2,338 crore reported in the September 2024 quarter.

Earnings call Divi's Laboratories posted a 25.4% YoY revenue growth for Q3 FY25, with PAT rising 64.5% YoY. Custom synthesis continues to drive growth, while backward integration via the new Kakinada ...

Divi's Laboratories recorded a decent set of numbers for the September quarter, with both profit and revenue rising ...

Telangana: Divi's Labs has announced that the US Food and Drug Administration (USFDA) has concluded an inspection with no 483 ...

Divis Laboratories Ltd has informed BSE that it has had a successful inspection by the US-FDA from 16th to 20th June, 2014, without any observations, for its Unit-I at vill. Lingojigudem, Choutuppal ...

BENGALURU, Feb 3 (Reuters) - Indian pharmaceutical firm Divi's Laboratories Ltd (DIVI.NS), opens new tab on Friday reported a third-quarter profit that widely missed analysts' estimates, hurt by ...

Earnings call Divi's Laboratories reported a 17% YoY revenue growth in Q2 FY26, driven by a record 56% contribution from custom synthesis. Margins remained resilient despite ongoing generic pricing ...